Business
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata
About this update from Zura Bio Limited
[{"type":"text","content":"\n\nInitiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata\n\n\n\nExperienced team building the next Immunology leader\n\n\n\nCash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026\n\n\n\n HENDERSON, Nev.--(BUSINESS WIRE)--\nZura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.\n\n\n\"In the third quarter, Zura Bio made significant progress in its strategic planning across various key areas, including Clinical, Regulatory, CMC, and Translational Science. This progress positions Zura Bio for clinical trial readiness in 2024,\" stated Dr. Someit Sidhu, Chief Executive Officer of Zura Bio. \"In support of the upcoming clinical trial for ZB-168, an anti-IL-7R monoclonal antibody intended for the treatment of alopecia areata, we achieved several milestones. These include the submission and feedback from a Type B meeting request to the United States Food and Drug Administration, the transfer of technology to our Contract Development and Manufacturing Organization, and the selection of a Contract Research Organization to assist with site selection and the initiation of trial activities in the coming months. Furthermore, we are excited to announce our collaboration with the Benaroya Research Institute through a sponsored research agreement. This collaboration aims to further our understanding of the pivotal role of IL-7Rα in TSLP and IL-7 signaling pathways. As we continue to strengthen our scientific rationale and gather more data, we look forward to sharing additional insights. Beyond our work on ZB-168, we are actively engaged in planning and collaboration with thought leaders and experts to advance our leading asset, ZB-106, in the treatment of systemic sclerosis and hidradenitis suppurativa. We anticipate commencing clinical activities in the second half of 2024.\"\n\n\nTHIRD QUARTER 2023 BUSINESS HIGHLIGHTS\n\n\n\nProgressed planning across three indications: ZB-168 is the first clinical trial to initiate in 2024 in alopecia ...